Group 1 - AbbVie is in talks to acquire Gilgamesh Pharmaceuticals, a company focused on mental health treatments, with a potential valuation of around $1 billion for Gilgamesh [1] - The acquisition discussions follow a selective licensing agreement signed over a year ago between AbbVie and Gilgamesh to co-develop new therapies for mental disorders [1] - Gilgamesh is developing a new generation of psychedelic compounds known as "neuroplastogens" aimed at treating depression, anxiety, substance addiction, and other mental health issues [1] Group 2 - If the acquisition is successful, it will enhance AbbVie's product pipeline in the mental health treatment sector, especially after a previous acquisition related to schizophrenia failed in mid-stage clinical trials [2] - AbbVie currently markets a drug named Vraylar for schizophrenia and bipolar disorder [2] - The potential deal highlights the growing merger and acquisition interest in the mental health treatment field, with Atai Life Sciences also exploring early acquisition interests from major industry players [2] Group 3 - Analysts predict that psychedelic drugs for treating depression may see significant breakthroughs in the next two years, with key trial data expected to be released [2] - Companies like MindMed, Cybin, and Gilgamesh are leading this rapidly evolving field, targeting a large but unmet patient population, with market forecasts predicting sales of approximately $4.5 billion by 2032 [2]